<DOC>
	<DOCNO>NCT01478152</DOCNO>
	<brief_summary>In single center , dose finding , safety study effect inhale Ectoin® inhalation solution investigate subject mild bronchial asthma . This dose-finding study estimate minimum effective dose ass safe dosage , term quantity give patient . The result compare baseline measurement . The result regard Sputum measurement compare measurement placebo administration .</brief_summary>
	<brief_title>Effect Ectoin® Inhalation Solution Subjects With Mild Bronchial Asthma</brief_title>
	<detailed_description>Based anti-inflammatory effect inhale Ectoin® show previous animal study , trial aim investigate effect term reduction unspecific bronchial hyperresponsiveness ( BHR ) Methacholine challenge test subject mild bronchial asthma . In addition , measurement exhale nitric oxide level indicator bronchial inflammation investigate . This study focus primarily safety dose find 12 18 subject mild bronchial asthma . After screen visit , subject treat placebo , follow increase dos Ectoin® ( low , medium high dose ) . All dose Ectoin® inhalation solution placebo administer 5 - 7 day .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Adults ( 18 65 year ) FEV1 ≥ 80 % predict patient 's normal value pre bronchodilator ( accord European Coal Steel Community reference value ) Positive Methacholine challenge test ( PD20 ≤ 0.5 mg ) A general practitioner consultant diagnose mild bronchial asthma Non ex smoker ( 6 month , pack year ( PY ) ≤ 5 ) Pregnant lactate female Participation another clinical study previous month Severe concomitant disease may impact study participation Hypersensibility Ectoin® Patients treatment live attenuate vaccination within 14 day prior screen visit ( Inactivated influenza vaccination acceptable , provide administer within 7 day prior screen visit ) . Other respiratory disease ( e.g . Chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , alpha1Antitrypsin deficiency , sarcoidosis , bronchiectasis , allergic alveolitis , tuberculosis , etc . ) Upper low airway respiratory infection within 4 week prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ectoin</keyword>
	<keyword>Ectoine</keyword>
	<keyword>FeNO</keyword>
	<keyword>Metacholin</keyword>
	<keyword>sRaw</keyword>
</DOC>